查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1390468

流感疫苗市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Influenza Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年全球流感疫苗市场价值达到62亿美元。展望未来， IMARC Group预计到2028年市场规模将达到98亿美元，2022-2028年CAGR为7.93%。人们对疫苗接种重要性的认识不断提高、流感盛行率上升以及政府推动疫苗接种计划的有利倡议是推动市场的一些主要因素。

流感疫苗，也称为流感疫苗，是一种预防性医疗产品，旨在提供对流感病毒的保护。它通常透过肌肉注射或鼻喷剂形式施用。该疫苗含有灭活或减弱的流感病毒株，促使免疫系统产生抗体。这些抗体可以帮助身体识别并防御接触到的实际病毒，从而降低感染的可能性和症状的严重程度。因此，建议所有年龄层的人都接种流感疫苗，尤其是併发症风险较高的人，例如幼儿、老年人和有潜在健康问题的人。

大众对疫苗接种在预防流感方面重要性的认识不断增强，将刺激预测期内市场的成长。随着人们健康意识的增强以及对免疫接种益处的了解，流感疫苗的使用率显着上升。此外，流感流行率的上升、季节性爆发和偶尔的流行病促使政府、医疗保健提供者和个人优先考虑接种疫苗作为预防措施，这对市场成长产生了积极影响。除此之外，旨在促进疫苗接种计划的几项有利的政府措施和公共卫生运动也促进了市场的成长。此外，许多国家推出疫苗接种活动、补贴疫苗分发和公众宣传活动也加快了产品的采用率。此外，人们越来越关注研发（R&D）活动，以开发更有效、保护更广泛的流感疫苗，这也促进了市场的成长。

流感疫苗市场趋势/驱动因素：

疫苗接种的意识和重要性不断增强

近年来，大众对流感疫苗接种重要性的认识显着提高。健康教育活动、透过各种媒体管道传播讯息以及医疗保健组织的努力极大地促进了这种意识的提高。随着人们健康意识的增强并了解免疫接种的好处，对流感疫苗的需求大幅上升。现在人们认识到，及时接种疫苗可以保护他们免于感染流感，并有助于防止流感传播给弱势群体。这种意识的提高导致社会对疫苗接种的态度发生转变，促使更多的人寻求并优先考虑流感疫苗接种作为一项重要的预防措施。

季节性流感爆发和流行病不断增加

季节性流感爆发的周期性发生，加上流感大流行的偶尔出现，仍然是推动市场成长的主要因素。每年，季节性流感的爆发都会对医疗保健系统造成沉重负担，导致住院率和劳动力缺勤率增加。此外，历史上流感大流行（如 2009 年 H1N1 流感大流行）的破坏性影响更凸显了采取预防措施的必要性。此类疫情和大流行凸显了流感病毒带来的潜在风险，并强调了疫苗接种对于保护个人和社区的重要性，从而推动了对流感疫苗的持续需求。

加大政府支持与倡议

世界各国政府透过各种支持机制和措施在促进流感疫苗接种方面发挥着至关重要的作用。他们越来越多地投资于疫苗接种活动，以提高人们对流感疫苗重要性的认识，并分配资金来购买和分发疫苗。许多国家为儿童、老年人和医护人员等优先群体提供补贴或免费疫苗接种，从而提高疫苗的可近性。政府推动的免疫计划和政策要求在学校或医疗机构等特定环境中接种疫苗，这进一步促进了流感疫苗的接种。政府的广泛支持为流感疫苗市场的成长创造了有利的环境，并有利于扩大人口覆盖范围，保护公众健康并减轻流感相关疾病的负担。

流感疫苗产业细分：

IMARC Group提供了全球流感疫苗市场报告各细分市场主要趋势的分析，以及 2023-2028 年全球、区域和国家层面的预测。我们的报告根据疫苗类型、技术、年龄层和给药途径对市场进行了分类。

依疫苗类型细分：

四价

三价

四价代表最受欢迎的流感疫苗类型

该报告根据疫苗类型对市场进行了详细的细分和分析。这包括四价和三价。根据该报告，四价代表了最大的细分市场。

四价疫苗类型可增强对多种流感病毒株的保护。与针对三种流感株（两种甲型流感株和一种乙型流感株）的传统三价疫苗不同，四价疫苗还包含一种额外的乙型流感株。这种扩大覆盖范围至关重要，因为乙型流感病毒经常表现出抗原漂移，导致三价疫苗可能无法充分涵盖的不同谱系的出现。透过提供更广泛的保护，四价疫苗可以更有效地预防流感感染并减轻疾病负担。

此外，由于四价疫苗覆盖范围广，医疗保健提供者和个人更喜欢四价疫苗，从而导致更高的需求和细分市场的成长。采用四价疫苗已成为许多疫苗接种计划的标准，鼓励製造商对其生产和分销进行投资，以满足全球对更有效和更全面的流感疫苗接种日益增长的需求。

按技术划分：

以鸡蛋为主

基于细胞的

蛋类占市场最大份额

报告还提供了基于该技术的详细市场细分和分析。这包括基于鸡蛋和基于细胞的。报告称，以鸡蛋为主的食品占据了最大的市场。

以鸡蛋为基础的技术是用于疫苗生产的常规方法之一，其中流感病毒株在鸡蛋中生长，然后收穫并加工用于疫苗製剂。儘管替代疫苗生产技术已广泛使用，但基于鸡蛋的方法由于其既定的安全性、可扩展性和成本效益而被广泛使用。许多领先的製造商拥有广泛的鸡蛋生产能力，使他们能够生产大量疫苗，以满足流感季节和疫情爆发期间的全球需求。

此外，随着对更具创新性和更快的疫苗生产的需求不断增长，製造商正在探索更新的技术，例如基于细胞和重组的方法。然而，基于鸡蛋的技术的传统继续推动该细分市场的成长，特别是在其仍然是主要生产方法的地区，确保全球流感疫苗的稳定供应。

按年龄组别划分：

儿科

成人

儿科占据市场主导地位

报告还提供了基于年龄组的详细市场细分和分析。这包括儿童和成人。报告显示，儿科占据了最大的市场份额。

儿科领域是流感疫苗市场的重要驱动力，因为它在保护婴幼儿免受流感和减少其在社区内传播方面发挥着至关重要的作用。儿童，尤其是五岁以下的儿童，更容易出现严重的流感相关併发症，因此疫苗接种对于保障他们的健康至关重要。儿童疫苗经过专门配製，可在年轻接种者中引发强烈的免疫反应，确保充分预防疾病。

此外，给儿童接种疫苗有助于建立群体免疫力，减少病毒向老年人和免疫系统受损的人等弱势群体的传播。因此，医疗保健提供者、政府和家长认识到儿童流感疫苗接种的重要性，导致对儿童流感疫苗的需求增加，从而推动了这一领域的成长。製造商不断创新并生产安全有效的儿科疫苗，有助于改善公共卫生结果并减轻流感的整体负担。

依给药途径分类：

注射

鼻喷剂

报告还根据给药途径对市场进行了详细的细分和分析。这包括注射和鼻喷剂。

注射剂和鼻喷剂的选择在满足个人喜好和需求方面发挥着至关重要的作用。虽然注射仍然是最广泛使用和首选的疫苗接种方法，但鼻喷剂提供了一种无针替代方案，尤其对儿童和有针恐惧症的个人有吸引力。这种双重方法提高了疫苗的整体接受度和使用率，有助于提高不同年龄层的疫苗接种率。

此外，鼻喷剂提供了一种更方便、更有效的疫苗输送方式，使医疗保健提供者能够在大规模疫苗接种活动或社区环境中更快速地接种疫苗。因此，注射剂和鼻喷剂的选择进一步扩大了疫苗接种的可及性并使疫苗接种选择多样化，从而确保了流感疫苗的更广泛覆盖范围。因此，製造商正在大力投资这两种交付方法，并认识到它们在促进公共卫生和遏制流感影响方面的重要性。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美在市场上表现出明显的主导地位

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（英国、德国、法国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美占据最大的市场份额。

北美占据了最大的市场份额，因为该地区拥有完善的医疗基础设施、高额医疗支出和先进的研究能力，为疫苗开发和分销创造了有利的环境。此外，该地区经历了季节性流感负担，促使医疗当局优先考虑疫苗接种计划和运动。此外，积极主动的政府倡议，例如公众宣传活动和补贴疫苗分发，有助于增加整个北美的疫苗接种率。

另一个主要贡献因素是人们对预防性医疗保健的日益重视以及人们对流感疫苗接种益处的认识不断提高。如今，製造商认识到北美市场的潜力，并正在投资研究和生产设施，以满足该地区的需求。

竞争格局：

随着製造商积极寻求创新策略以提高疫苗功效、可近性和便利性，市场正在稳定成长。此外，更先进和具有广泛保护性的疫苗的开发正在推动市场成长。各个主要参与者正在增加与研究相关的努力，以创造能够更好地预防多种流感病毒株的疫苗，减少频繁更新的需要并提高整体有效性。此外，疫苗生产技术的进步，例如基于细胞和重组技术，使得生产速度更快、规模更大，确保了季节性需求激增和潜在疫情期间的稳定供应。此外，人们正在努力改进疫苗输送方法，开发无针疫苗，包括皮内或鼻喷疫苗。此类创新有助于解决疫苗犹豫问题并促进更广泛的疫苗接种覆盖面，从而加强对抗流感及其对全球公共卫生的影响。我们也预期市场将出现新进业者、主要参与者之间加强合作以及持续的产品创新，以推动流感疫苗产业内的健康竞争。

该报告对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。市场上的一些主要参与者包括：

雅培实验室

阿斯特捷利康公司

中超有限公司

第一三共株式会社

紧急生物解决方案公司

F.霍夫曼-拉罗氏股份公司

伽玛疫苗有限公司

葛兰素史克公司

默克公司

诺华公司

辉瑞公司

赛诺菲

科兴

最近的发展：

2021 年 2 月，葛兰素史克扩大了与 Vir Biotechnology 的合作，标誌着应对流感预防和治疗全球挑战的策略性倡议。此次合作旨在开发单株抗体，这是一种可以特异性中和流感病毒的标靶疗法。单株抗体在针对病毒感染提供预防（预防）和治疗（治疗）益处方面显示出巨大的潜力。

2022年9月，辉瑞公司启动了以mRNA为基础的流感疫苗的第3期临床研究。该候选疫苗采用改良 RNA 技术，该技术在其他疫苗（包括基于 mRNA 的 COVID-19 疫苗）中显示出了巨大的前景。该研究招募了 25,000 名 18 岁及以上的美国成年人，反映了试验的广泛范围和疫苗的潜在目标族群。透过纳入大量参与者，该试验旨在收集有关疫苗安全性、有效性、免疫原性（触发免疫反应的能力）和耐受性的可靠资料。

2021 年 9 月，赛诺菲收购了临床阶段 mRNA 治疗公司 Translate Bio，用于开发新型季节性流感疫苗。此次收购符合该公司致力于推进创新医疗保健解决方案并增强其在 mRNA 治疗领域能力的承诺。透过将 Translate Bio 的专业知识和资源纳入旗下，赛诺菲获得了最先进的 mRNA 疫苗平台和研究管道，这可以显着加速下一代流感疫苗的开发。

本报告回答的关键问题

  • 2022年全球流感疫苗市场规模是多少
  • 2023-2028年全球流感疫苗市场预计成长率是多少
  • 推动全球流感疫苗市场的关键因素是什么
  • 推动全球流感疫苗市场的关键因素是什么
  • COVID-19 对全球流感疫苗市场有何影响
  • 根据疫苗类型，全球流感疫苗市场的细分如何
  • 基于技术的全球流感疫苗市场区隔如何
  • 全球流感疫苗市场依年龄层划分是怎样的
  • 全球流感疫苗市场的重点区域有哪些
  • 10. 全球流感疫苗市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2022年全球流感疫苗市场规模有多大？
  • 2023-2028年全球流感疫苗市场的预期成长率是多少？
  • 推动全球流感疫苗市场的关键因素是什么？
  • 推动全球流感疫苗市场的关键因素是什么？
  • COVID-19 对全球流感疫苗市场有何影响？
  • 根据疫苗类型，全球流感疫苗市场的细分情况如何？
  • 基于科技的全球流感疫苗市场区隔如何？
  • 全球流感疫苗市场依年龄层划分是怎样的？
  • 全球流感疫苗市场的重点区域有哪些？
  • 全球流感疫苗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球流感疫苗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按疫苗类型分類的市场区隔

  • 四价
    • 市场走向
    • 市场预测
  • 三价
    • 市场走向
    • 市场预测

第 7 章：依科技分類的市场

  • 以鸡蛋为主
    • 市场走向
    • 市场预测
  • 基于细胞的
    • 市场走向
    • 市场预测

第 8 章：按年龄组别分類的市场区隔

  • 儿科
    • 市场走向
    • 市场预测
  • 成人
    • 市场走向
    • 市场预测

第 9 章：按管理途径分類的市场

  • 注射
    • 市场走向
    • 市场预测
  • 鼻喷剂
    • 市场走向
    • 市场预测

第 10 章：按地区分類的市场细分

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • AstraZeneca plc
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gamma Vaccines Pty Ltd
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • SINOVAC
Product Code: SR112023A4206

Abstract

The global influenza vaccine market reached a value of US$ 6.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.8 Billion by 2028, exhibiting a CAGR of 7.93% during 2022-2028. The increasing awareness about the importance of vaccination, rising prevalence of influenza, and favorable government initiatives promoting vaccination programs are some of the major factors propelling the market.

An influenza vaccine, also known as a flu vaccine, is a preventive medical product designed to provide protection against influenza viruses. It is typically administered through an injection into the muscle or as a nasal spray. The vaccine contains inactivated or weakened strains of the influenza virus, prompting the immune system to produce antibodies. These antibodies help the body recognize and defend against the actual virus if exposed, reducing the likelihood of infection and the severity of symptoms. As a result, influenza vaccine is recommended for individuals of all ages, especially those at higher risk of complications, such as young children, elderly individuals, and people with underlying health conditions.

The increasing awareness among the masses about the significance of vaccination in preventing influenza will stimulate the growth of the market during the forecast period. As people become more health-conscious and educated about the benefits of immunization, the uptake of influenza vaccines has risen significantly. Moreover, the rising prevalence of influenza, seasonal outbreaks, and occasional pandemics are prompting governments, healthcare providers, and individuals to prioritize vaccination as a preventive measure, which is positively influencing the market growth. Apart from this, several favorable government initiatives and public health campaigns aimed at promoting vaccination programs has catalyzed the market growth. Additionally, the introduction of vaccination drives, subsidized vaccine distribution, and public awareness campaigns across numerous countries has accelerated the product adoption rate. Furthermore, the increasing focus on research and development (R&D) activities to develop more effective and broadly protective influenza vaccines is contributing to the market growth.

Influenza Vaccine Market Trends/Drivers:

Growing awareness and importance of vaccination

In recent years, there has been a notable increase in public awareness about the importance of influenza vaccination. Health education campaigns, information dissemination through various media channels, and efforts by healthcare organizations have significantly contributed to this growing awareness. As people become more health-conscious and informed about the benefits of immunization, the demand for influenza vaccines has risen substantially. Individuals now recognize that timely vaccinations can protect them from contracting the flu as well as help prevent its spread to vulnerable populations. This heightened awareness has led to a shift in societal attitudes toward vaccination, driving more people to seek and prioritize flu vaccination as a crucial preventive measure.

Rising seasonal influenza outbreaks and pandemics

The cyclical occurrence of seasonal influenza outbreaks, coupled with the occasional emergence of influenza pandemics, continues to be a major factor propelling the market growth. Each year, seasonal flu outbreaks result in a significant burden on healthcare systems, with increased hospitalization rates and workforce absenteeism. Moreover, the devastating impact of historical influenza pandemics, like the H1N1 pandemic in 2009, has reinforced the need for preventive measures. Such outbreaks and pandemics highlight the potential risks posed by the influenza virus and underscore the importance of vaccination to protect individuals and communities, driving sustained demand for influenza vaccines.

Increasing government support and initiatives

Governments worldwide play a crucial role in promoting influenza vaccination through various support mechanisms and initiatives. They are increasingly investing in vaccination campaigns to raise awareness about the importance of flu shots and allocating funds to procure and distribute vaccines. Many countries offer subsidized or free vaccination for priority groups, such as children, elderly individuals, and healthcare workers, thereby improving vaccine accessibility. Government-driven immunization programs and policies mandate vaccination in certain settings, such as schools or healthcare facilities, further contributing to influenza vaccine uptake. This extensive governmental support creates a conducive environment for the growth of the influenza vaccine market and facilitates broader population coverage, protecting public health and reducing the burden of influenza-related illnesses.

Influenza Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza vaccine market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

Quadrivalent

Trivalent

Quadrivalent represents the most popular type of influenza vaccine

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes quadrivalent and trivalent. According to the report, quadrivalent represented the largest segment.

The quadrivalent vaccine type offers enhanced protection against multiple influenza strains. Unlike the traditional trivalent vaccines, which target three flu strains (two influenza A strains and one influenza B strain), the quadrivalent vaccine includes an additional influenza B strain. This expanded coverage is crucial as influenza B viruses often exhibit antigenic drift, leading to the emergence of distinct lineages that may not be adequately covered by trivalent vaccines. By offering broader protection, quadrivalent vaccines are more effective in preventing influenza infections and reducing the burden of the disease.

Furthermore, healthcare providers and individuals are preferring quadrivalent vaccines owing to their comprehensive coverage, leading to a higher demand and segment growth. The adoption of quadrivalent vaccines has become a standard in many vaccination programs, encouraging manufacturers to invest in their production and distribution to meet the rising global demand for more effective and comprehensive influenza vaccination.

Breakup by Technology:

Egg-based

Cell-based

Egg-based holds the largest share in the market

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes egg-based and cell-based. According to the report, egg-based accounted for the largest market share.

Egg-based technology is one of the conventional methods used for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being harvested and processed for vaccine formulation. Despite the widespread availability of alternative vaccine production technologies, the egg-based method has been widely utilized due to its established safety, scalability, and cost-effectiveness. Many leading manufacturers have extensive egg-based production capabilities, allowing them to produce large quantities of vaccines to meet global demand during flu seasons and pandemic outbreaks.

Moreover, as the demand for more innovative and faster vaccine production grows, manufacturers are exploring newer technologies such as cell-based and recombinant approaches. However, the legacy of egg-based technology continues to drive the segment growth, particularly in regions where it remains the predominant production method, ensuring a stable supply of influenza vaccines worldwide.

Breakup by Age Group:

Pediatric

Adult

Pediatric dominates the market

A detailed breakup and analysis of the market based on the age group has also been provided in the report. This includes pediatric and adult. According to the report, pediatric accounted for the largest market share.

The pediatric segment is a significant driver of the market for influenza vaccine due to its vital role in protecting infants and young children from influenza and reducing its spread within communities. Children, especially those under the age of five, are more susceptible to severe flu-related complications, making vaccination crucial in safeguarding their health. Pediatric vaccines are specifically formulated to elicit a robust immune response in young recipients, ensuring adequate protection against the disease.

Moreover, vaccinating children helps create herd immunity, reducing the transmission of the virus to vulnerable populations, such as the elderly and individuals with compromised immune systems. As a result, healthcare providers, governments, and parents recognize the importance of pediatric influenza vaccination, leading to a higher demand for pediatric flu vaccines, thus fueling the growth of this segment. Manufacturers continue to innovate and produce safe and effective pediatric vaccines, contributing to better public health outcomes and reducing the overall burden of influenza.

Breakup by Route of Administration:

Injection

Nasal Spray

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes injection and nasal spray.

The availability of both injection and nasal spray options plays a crucial role in catering to individual preferences and needs. While the injection remains the most widely used and preferred method for vaccine administration, the nasal spray provides a needle-free alternative, especially appealing to children and individuals with needle phobia. This dual approach increases overall vaccine acceptance and uptake, contributing to higher vaccination rates across different age groups.

Additionally, the nasal spray offers a more convenient and efficient mode of vaccine delivery, enabling healthcare providers to administer vaccines more rapidly during large-scale vaccination campaigns or in community settings. As a result, the availability of both injection and nasal spray options further expands accessibility and diversifies vaccination choices, ensuring broader coverage for influenza vaccines. Therefore, manufacturers are heavily investing in both delivery methods, recognizing their importance in promoting public health and curbing the impact of influenza.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (the United Kingdom, Germany, France, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a well-established healthcare infrastructure, high healthcare expenditure, and advanced research capabilities that foster a conducive environment for vaccine development and distribution. Moreover, the region experiences a seasonal burden of influenza, prompting healthcare authorities to prioritize vaccination programs and campaigns. In addition, proactive government initiatives, such as public awareness campaigns and subsidized vaccine distribution, contribute to increased vaccine uptake across North America.

Another major contributing aspect is the growing emphasis on preventive healthcare and the increasing awareness among the population about the benefits of influenza vaccination. Manufacturers today recognize the potential of the North American market and are investing in research and production facilities to cater to the region's needs.

Competitive Landscape:

The market is experiencing steady growth as manufacturers are actively pursuing innovative strategies to enhance vaccine efficacy, accessibility, and convenience. Moreover, the development of more advanced and broadly protective vaccines is driving the market toward growth. Various key players are increasing their research-related efforts to create vaccines that offer better protection against multiple influenza strains, reducing the need for frequent updates and improving overall effectiveness. Additionally, advancements in vaccine production techniques, such as cell-based and recombinant technologies, have enabled faster and more scalable manufacturing, ensuring a steady supply during seasonal demand surges and potential pandemics. Moreover, efforts are being made to improve vaccine delivery methods, with the development of needle-free options, including intradermal or nasal spray vaccines. Such innovations help address vaccine hesitancy and facilitate broader vaccination coverage, thus strengthening the fight against influenza and its impact on global public health. We also expect the market to witness new entrants, increased partnerships among key players, and continual product innovations to drive healthy competition within the influenza vaccine industry.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AstraZeneca plc

CSL Limited

Daiichi Sankyo Company Limited

Emergent BioSolutions Inc.

F. Hoffmann-La Roche AG

Gamma Vaccines Pty Ltd

GlaxoSmithKline plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

SINOVAC

Recent Developments:

In February 2021, GlaxoSmithKline plc expanded its collaboration with Vir Biotechnology, signifying a strategic move to address the global challenge of influenza prevention and treatment. This collaboration aims to develop monoclonal antibodies, a type of targeted therapy that can specifically neutralize the influenza virus. Monoclonal antibodies have shown promising potential in providing both prophylactic (preventive) and therapeutic (treatment) benefits against viral infections.

In September 2022, Pfizer Inc. initiated the phase 3 clinical study for mRNA-based influenza vaccine. This vaccine candidate utilizes modified RNA technology, which has shown great promise in other vaccines, including the mRNA-based COVID-19 vaccines. The study enrolled 25,000 U.S. adults aged 18 years and older, reflecting the broad scope of the trial and the potential target population for the vaccine. By including a substantial number of participants, the trial aims to gather robust data on the vaccine's safety, efficacy, immunogenicity (ability to trigger an immune response), and tolerability.

In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company, for the development of new and seasonal vaccines for influenza. The acquisition aligns with the company's commitment to advancing innovative healthcare solutions and enhancing its capabilities in the field of mRNA-based therapeutics. By bringing Translate Bio's expertise and resources under its umbrella, Sanofi has gained access to cutting-edge mRNA vaccine platforms and research pipelines, which can significantly accelerate the development of next-generation influenza vaccines.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza vaccine market in 2022?
  • 2. What is the expected growth rate of the global influenza vaccine market during 2023-2028?
  • 3. What are the key factors driving the global influenza vaccine market?
  • 4. What are the key factors driving the global influenza vaccine market?
  • 5. What has been the impact of COVID-19 on the global influenza vaccine market?
  • 6. What is the breakup of the global influenza vaccine market based on the vaccine type?
  • 7. What is the breakup of the global influenza vaccine market based on the technology?
  • 8. What is the breakup of the global influenza vaccine market based on the age group?
  • 9. What are the key regions in the global influenza vaccine market?
  • 10. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Quadrivalent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Trivalent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Egg-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adult
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Injection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Nasal Spray
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CSL Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Daiichi Sankyo Company Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Gamma Vaccines Pty Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck & Co. Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Novartis AG
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 SINOVAC
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials

List of Figures

  • Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2022
  • Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2022
  • Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2022
  • Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2022
  • Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: China: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: India: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: France: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2022
  • Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
  • Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
  • Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2023-2028
  • Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million US$), 2023-2028
  • Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Influenza Vaccine Market: Competitive Structure
  • Table 8: Global: Influenza Vaccine Market: Key Players